US EditionHRS Releases Framework for Creating Atrial Fibrillation Center of Excellence
Summary by DAIC
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
XYRA Announces the Issuance of a Fifth New US Patent in a Series of Patents Which Protect the Use of Budiodarone in the Management of Atrial Fibrillation till after 2040
Budiodarone shown in Phase 2 to reduce atrial fibrillation symptoms and long episodes of atrial fibrillation (LEAF)FDA gives guidance on steps necessary to gain approval and incorporate wearable AF monitoring devices into label for budiodaroneFive granted US patents align with…
·United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
